Science Reviews - Biology, 2024, 3(2), 1-12 Aishani Kumar, Thendral Yalini, Sunil Kumar C
1
Unlocking Cellular Control: The Promise of PROTACs
in Disease Intervention
Aishani Kumar, Thendral Yalini, Sunil Kumar C
Affiliated with PES University, Bangalore, India; aishbijit@gmail.com, thendral2002@gmail.com, sunilkumarc@pes.edu
References
1. Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019). Cereblon versus VHL:
Hijacking E3 ligases against each other using PROTACs. Bioorganic & Medicinal Chemistry, 27(12),
24662479. doi:10.1016/j.bmc.2019.02.048
2. Khodavirdipour, Amir, et al. "Apoptosis detection methods in diagnosis of cancer and their
potential role in treatment: advantages and disadvantages: a review." Journal of Gastrointestinal
Cancer 52 (2021): 422-430
3. Troup, Robert I., Charlene Fallan, and Matthias GJ Baud. "Current strategies for the design of
PROTAC linkers: a critical review." Exploration of Targeted Anti-tumor Therapy 1.5 (2020): 273.
4. Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020). Degradation of proteins by PROTACs and
other strategies. Acta Pharmaceutica Sinica. B, 10(2), 207238. doi:10.1016/j.apsb.2019.08.001
5. Rutqvist, L. E. "Radiation therapies for breast cancer: current knowledge on advantages and
disadvantages." Adjuvant Therapy of Breast Cancer IV (1993):
119-127.
6. Reddy Chichili, V. P., Kumar, V., & Sivaraman, J. (2013). Linkers in the structural biology of
proteinprotein interactions. Protein Science: A Publication of the Protein Society, 22(2), 153167.
doi:10.1002/pro.2206
7. Sang, Y., Yan, F., & Ren, X. (2015). The role and mechanism of CRL4 E3 ubiquitin ligase in cancer
and its potential therapy implications. Oncotarget, 6(40), 4259042602. doi:10.18632/oncotarget.6052
8. Vittal, V., Stewart, M., Brzović, P. S., & Klevit, R. E. (2015). Regulating the regulators: Recent
revelations in the control of E3 ubiquitin ligases. Journal of Biological Chemistry, 290(35), 21244
21251. https://doi.org/10.1074/jbc.r115.675165
9. Garber, Ken. "The PROTAC gold rush." Nat. Biotechnol 40.1 (2022): 12-16.
10. Békés, Miklós, David R. Langley, and Craig M. Crews. "PROTAC targeted protein degraders:
the past is prologue." Nature Reviews Drug Discovery 21.3 (2022): 181-200.
11. Paiva, Stacey-Lynn, and Craig M. Crews. "Targeted protein degradation: elements of PROTAC
design." Current opinion in chemical biology 50 (2019): 111-119.
12. Nalawansha, Dhanusha A., and Craig M. Crews. "PROTACs: an emerging therapeutic modality
in precision medicine." Cell chemical biology 27.8 (2020): 998-1014.
13. Li, Ke, and Craig M. Crews. "PROTACs: past, present and future." Chemical Society Reviews 51.12
(2022): 5214-5236
14. Liu, Jing, et al. "PROTACs: A novel strategy for cancer therapy." Seminars in Cancer Biology.
Vol. 67. Academic Press, 2020.
15. Li, Xintong, et al. "c-Myc-targeting PROTAC based on a TNA-DNA bivalent binder for
combination therapy of triple-negative breast cancer." Journal of the American Chemical Society
145.16 (2023): 9334-9342.
Aishani Kumar, Thendral Yalini, Sunil Kumar C Science Reviews - Biology, 2024, 3(2), 1-12
2
16. Toure, Momar, and Craig M. Crews. "Smallmolecule PROTACS: new approaches to protein
degradation." Angewandte Chemie International Edition 55.6 (2016): 1966-1973.
17. Ebrahimi, Mehdi, et al. "Synthesis and characterization of biomimetic bioceramic nanoparticles
with optimized physicochemical properties for bone tissue engineering." Journal of Biomedical
Materials Research Part A 107.8 (2019): 1654-1666.
18. Neklesa, Taavi, et al. "ARV-110: An oral androgen receptor PROTAC degrader for prostate
cancer." J. Clin. Oncol 37.259 (2019): 10-1200.
19. Raina, Kanak, et al. "PROTAC-induced BET protein degradation as a therapy for castration-
resistant prostate cancer." Proceedings of the National Academy of Sciences 113.26 (2016): 7124-7129.
20. Snyder, Lawrence B., et al. "The discovery of ARV-471, an orally bioavailable estrogen receptor
degrading PROTAC for the treatment of patients with breast cancer." Cancer Res 81.13 (2021): 44.
21. Pöstges, Florian, et al. "Solubility enhanced formulation approaches to overcome oral delivery
obstacles of PROTACs." Pharmaceutics 15.1 (2023): 156.
22. Benowitz, Andrew B., Paul T. Scott-Stevens, and John D. Harling. "Challenges and opportunities
for in vivo PROTAC delivery." Future Medicinal Chemistry 14.3 (2022): 119-121.
23. Chen, Yu, et al. "Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein
degraders towards clinical translation." Chemical Society Reviews 51.13 (2022): 5330-5350.
24. Ebrahimi, M., Botelho, M., Lu, W., & Monmaturapoj, N. (2019). Synthesis and characterization of
biomimetic bioceramic nanoparticles with optimized physicochemical properties for bone tissue
engineering. Journal of Biomedical Materials Research Part A, 107(7), 1461-1472.
https://doi.org/10.1002/jbm.a.36681
25. Moon, Y.; Jeon, S.I.; Shim, M.K.; Kim, K. Cancer-Specific Delivery of Proteolysis-Targeting
Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics 2023,
15, 411.https://doi.org/10.3390/pharmaceutics1502041
26. Zhang, X., Chen, G., Zhang, H., Shang, L., & Zhao, Y. (2023). Bioinspired oral delivery devices.
Nature Reviews Bioengineering, 1, 208225.
27. Békés, M., Langley, D.R. & Crews, C.M. PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov 21, 181200 (2022). https://doi.org/10.1038/s41573-021-00371-6
28. Kou, Ponien, et al. "Development of Liposome Systems for Enhancing the PK Properties of
Bivalent PROTACs." Pharmaceutics 15.8 (2023): 2098.
29. Juan, Alberto, et al. "Options to improve the action of PROTACs in cancer: development of
controlled delivery nanoparticles." Frontiers in Cell and Developmental Biology 9 (2022): 805336.
30. Deng, Yuanfei, et al. "ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress
hepatocellular carcinoma progression." Frontiers in Pharmacology 13 (2022): 858901.
31. Schott, Anne F., et al. "Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER)
degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative
breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study." Cancer Research
83.5_Supplement (2023): GS3-03.